Barbara Pittore*, Carlo Loris Pelagatti, Lisa Fraser, Mauro Cau, Francesco Deiana, and Giovanni Sotgiu
Abstract:
Objective: To evaluate if oral Tranexamic Acid can decrease the proportion of individuals with secondary bleeding in the post-operative adeno-tonsillectomy phase.
Study design: Observational, retrospective epidemiological study.
Setting: San Francesco Hospital, Nuoro, Italy
Patients and methods: Over 20 months 236 children underwent elective adeno-tonsillectomy for chronic tonsillitis and/or otitis media and/or adenotonsillar hypertrophy. Two groups of patients were identified: the first one included 149 patients who took oral Tranexamic Acid (20 mg/Kg daily) for 10 days in the post-operative period, whereas the second one was characterized by 87 patients who did not take Tranexamic Acid.
Results: Only 6/236 (2.54%) cases of secondary bleeding were reported; 3/149 (2.01%) belonged to the group taking Tranexamic Acid, whereas 3/87 (3.44%; p-value: 0.5) belonged to the group not exposed to Tranexamic Acid. They were admitted and followed-up for 48 hours; no surgical interventions were performed.
Conclusion: Oral Tranexamic Acid did not significantly decrease the proportion of post-adenotonsillectomy bleeding episodes in our cohort. New prospective, randomized, controlled trials are needed to test the effectiveness of that drug in the management of post-adenotonsillectomy hemorrhages episodes.
Objective: To evaluate if oral Tranexamic Acid can decrease the proportion of individuals with secondary bleeding in the post-operative adeno-tonsillectomy phase.
Study design: Observational, retrospective epidemiological study.
Setting: San Francesco Hospital, Nuoro, Italy
Patients and methods: Over 20 months 236 children underwent elective adeno-tonsillectomy for chronic tonsillitis and/or otitis media and/or adenotonsillar hypertrophy. Two groups of patients were identified: the first one included 149 patients who took oral Tranexamic Acid (20 mg/Kg daily) for 10 days in the post-operative period, whereas the second one was characterized by 87 patients who did not take Tranexamic Acid.
Results: Only 6/236 (2.54%) cases of secondary bleeding were reported; 3/149 (2.01%) belonged to the group taking Tranexamic Acid, whereas 3/87 (3.44%; p-value: 0.5) belonged to the group not exposed to Tranexamic Acid. They were admitted and followed-up for 48 hours; no surgical interventions were performed.
Conclusion: Oral Tranexamic Acid did not significantly decrease the proportion of post-adenotonsillectomy bleeding episodes in our cohort. New prospective, randomized, controlled trials are needed to test the effectiveness of that drug in the management of post-adenotonsillectomy hemorrhages episodes.
No comments:
Post a Comment